Banca de QUALIFICAÇÃO: BÁRBARA ARAUJO FIDELLIS

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : BÁRBARA ARAUJO FIDELLIS
DATE: 22/05/2024
TIME: 09:00
LOCAL: meet.google.com/jvz-wcbt-udu
TITLE:

The use of the α-Gal epitope in the serological diagnosis of chronic Trypanosoma cruzi infection and pharmacotherapeutic follow-up.

KEY WORDS:

Chagas disease. VLP. Serology. Benznidazole.

PAGES: 60
BIG AREA: Ciências Biológicas
AREA: Parasitologia
SUBÁREA: Protozoologia de Parasitos
SPECIALTY: Protozoologia Parasitária Humana
SUMMARY:

The diagnosis of Trypanosoma cruzi infection in the chronic phase, as well as monitoring the effectiveness of the etiological treatment, are based on the detection of IgG anti-T. cruzi produced by infected individuals,  generally using protein antigens. However, the use of carbohydrate antigens present on the surface of the parasite has demonstrated great potential for this purpose. Thus, this work aimed to evaluate the performance of Qβ(α-Gal) 540 in the serological diagnosis of chronic T. cruzi infection and in monitoring the tiological pharmacotherapeutic efficacy. A total of 118 samples from individuals with reactive serology and 46 non- reactive for T. cruzi were tested against antigens obtained from the total extract of epimastigote forms of T. cruzi and Qβ(α-Gal) 540 , as well as 85 samples from 23 patients undergoing etiological treatment with benznidazole. The results showed a significant difference between the groups of individuals with reactive and non-reactive serology for both antigens, and no sample from negative individuals showed reactivity against the Qβ(α-Gal) 540 , showing values of 100% for specificity and positive predictive value. Regarding sensitivity, the total antigen obtained 55.08%, while Qβ(α-Gal) 540 presented 88.98%. The other parameters analyzed also showed a better result for the Qβ(α-Gal) 540 antigen, with a negative predictive value and accuracy of 77.97% and 92.07%, respectively. The reactivity profiles of the samples from the 23 patients before and after treatment with benznidazole against Qβ(α-Gal) 540 were more regular when compared to the crude antigen, most of which showed statistically significant differences. Thus, Qβ(α-Gal) 540 presents itself as a potential antigenic alternative in the diagnosis of chronic T. cruzi infection, as well as in monitoring pharmacotherapeutic efficacy, while reinforcing the need for other studies that explore its application in extended to the population of other geographic regions and with a longer follow-up period after etiological treatment.

COMMITTEE MEMBERS:
Presidente - 2611909 - CARLOS RAMON DO NASCIMENTO BRITO
Interno - 1752367 - PAULO MARCOS DA MATTA GUEDES
Interna - 1715271 - RENATA ANTONACI GAMA
Interno - 2213126 - VALTER FERREIRA DE ANDRADE NETO